|
Coronary Arteriosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In a necropsy study, we used immunohistochemistry to explore where and to what extent CCL2 and related receptors are present in diseased arteries that caused the death of men with coronary artery disease compared with unaffected arteries.
|
31739217 |
2020 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Associations of baseline uEGF, uMCP-1 and uEGF/MCP-1 with kidney outcome were assessed in a longitudinal cohort (n = 208) of advanced-stage DKD.
|
30357416 |
2020 |
|
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We previously showed that naringenin, a citrus flavonoid, suppressed macrophage infiltration into adipose tissue by inhibiting monocyte chemoattractant protein-1 (MCP-1) expression in the progression phase to high-fat diet (HFD)-induced obesity.
|
31218550 |
2020 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conclude hypoxia or obesity induces release of inflammatory TNFα and MCP-1 from mice primary adipocytes but the two environmental conditions do not synergize to worsen macrophage signal transduction or insulin responsiveness.
|
31677795 |
2020 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
RESULTS The levels of serum IgE and IgG in BLA- or Dex- treated mice were significantly reduced compared to those in the asthma (AS) group (P<0.01), whereas the levels of cytokines IL-4, TNF-α, and MCP-1 were significantly decreased (P<0.01).
|
30828084 |
2019 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Overall, we found no significant association between MCP-1 -2518A>G polymorphism and asthma susceptibility in any of the genetic model comparisons.
|
31664304 |
2019 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Higher relative abundance of these bacteria is furthermore associated with an airway immune profile dominated by reduced TNF-α and IL-1β and increased CCL2 and CCL17, which itself is an independent predictor for asthma.
|
31676759 |
2019 |
|
Coronary Arteriosclerosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Genetically determined higher MCP-1 levels were further associated with coronary artery disease (OR, 1.04; 95% CI, 1.00-1.08; P=0.04) and myocardial infarction (OR, 1.05; 95% CI, 1.01-1.09; P=0.02), but not with atrial fibrillation.
|
30586705 |
2019 |
|
Coronary Arteriosclerosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Regulatory Factor X1 Downregulation Contributes to Monocyte Chemoattractant Protein-1 Overexpression in CD14+ Monocytes <i>via</i> Epigenetic Mechanisms in Coronary Heart Disease.
|
31737059 |
2019 |
|
Coronary Arteriosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Effects of crocin and saffron aqueous extract on gene expression of SIRT1, AMPK, LOX1, NF-κB, and MCP-1 in patients with coronary artery disease: A randomized placebo-controlled clinical trial.
|
31797473 |
2019 |
|
Coronary Arteriosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent studies have indicated that monocyte chemoattractant protein-1 (MCP-1) plays an important role in the initiation and progression of ischaemic heart disease.
|
31077149 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent evidence demonstrates that this anti-hyperglycaemic drug exerts renal protective effects, yet the mechanisms remain poorly understood. monocyte chemoattractant protein 1 (MCP-1) has been recognized as a key mediator of renal fibrosis in chronic kidney diseases, including diabetic nephropathy.
|
29934960 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the expression of MCP-1 under high glucose conditions, as well as the effects of microRNA-192 (miR-192) under these conditions, and to study the regulatory mechanism of MCP-1 in DKD.
|
30827272 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conversely, levels of interleukin (IL)-1, IL-6, tumour necrosis factor-α and monocyte chemotactic protein-1 were higher in the DN group than in the control group.
|
29999450 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mechanistic studies reveal that pathways relevant to inflammation participate in the pathogenesis of DN, however, consumption of vitamin D-related products negatively regulates inflammatory response at multiple levels, indicated by inhibiting macrophage infiltration, nuclear factor-kappa B (NF-κB) activation, and production of such inflammatory mediators as transforming growth factor-β(TGF-β), monocyte chemoattractant protein 1(MCP-1), and regulated upon activation normal T cell expressed and secreted protein(RANTES).
|
30287151 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with DN group, the levels of TNF-α, IL-6, IL-1β, and MCP-1 were decreased in the PS-H group (p < 0.05).
|
31117104 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, correlations between urinary monocyte chemoattractant protein-1 and glycemic and inflammatory marker levels revealed the role of hyperglycemia and chronic inflammation in the pathogenesis of diabetic kidney disease.
|
31250339 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Chemokines such as C-C motif chemokine ligand 2 (CCL2), and pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β), are upregulated both peripherally and centrally in hypertension.
|
31427987 |
2019 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
MCP-1 expression in endothelial cells treated with uremic serum from ESRD patients with hypertension only was significantly increased compared with its expression in other cohorts.
|
31312972 |
2019 |
|
Kidney Failure, Chronic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MCP-1 expression in endothelial cells treated with uremic serum from ESRD patients with hypertension only was significantly increased compared with its expression in other cohorts.
|
31312972 |
2019 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Comparison of the <i>MCP-1</i> gene polymorphism distribution in ESRD patients with various primary diseases leading to ESRD did not show any significant differences.
|
31847640 |
2019 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Combined treatment of PA and LPS in RAW264.7 cells mimics the situation of diabetes with obesity that has higher level of PA and LPS, MAPK/TLR4/ MCP-1 might be potential therapeutic targets for diabetes with obesity.
|
30909920 |
2019 |
|
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Obese-ALI animals, compared to Obese-SAL, exhibited increased interventricular septum thickness (<i>p</i> = 0.003) and posterior wall thickness (<i>p</i> = 0.003) and decreased pulmonary acceleration time to pulmonary ejection time ratio (<i>p</i> = 0.005); no changes in lung mechanics, IL-6, TNF-α, TGF-β, PCIII, and PCI in lung tissue; increased IL-10 levels in lung homogenate (<i>p</i> = 0.007); reduced MCP-1 expression in blood neutrophils (<i>p</i> = 0.009); decreased TNF-α expression in blood (<i>p</i> = 0.02) and BALF (<i>p</i> = 0.008) neutrophils; and increased IL-10 expression in monocytes (<i>p</i> = 0.004).
|
31275296 |
2019 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, the level of urinary monocyte chemoattractant protein‑1 (u‑MCP‑1) was increased in the participants with obesity, and it was positively correlated with free fatty acid (FFA), UACR and u‑NGAL.
|
30535458 |
2019 |
|
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Obesity is associated to a low-grade inflammation that alters the expression of adiponectin, leptin, IL-6, Monocyte Chemotactic Protein 1 (MCP1), TRAIL, LIGHT/TNFSF14, OPG, and TNFα.
|
31130918 |
2019 |